Cytiva launches new ÄKTA readyflux system for smaller scale manufacturing

Designed to support drug developers in bringing their therapeutics to market faster, more efficiently, and with greater reliability

29 Jul 2025

Product news

Cytiva is expanding its ÄKTA portfolio with the addition of a system designed to optimize smaller-scale manufacturing. The ÄKTA readyflux™ TFF system 500 was developed in direct response to customer feedback indicating a rising need for efficient handling of low-volume applications in advanced therapeutic development, including viral vectors, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and mRNA-based therapeutics. 

ÄKTA readyflux TFF system 500 addresses industry challenges:

  • Scalability: For drug developers who struggle with scaling their processes from small-scale development to clinical and commercial manufacturing, the ÄKTA readyflux TFF system 500 offers scalability, while reducing risks and ensuring a smooth transition across different stages of development.
  • Efficiency in low-volume applications: The system is designed to handle applications such as viral vectors, mAbs, ADCs, and mRNA-based treatments efficiently, enabling maximum recovery with minimal loss.
  • Technology transfers: Moving processes from one stage of development to another can be complex and time-consuming. The system simplifies technology transfers, making the process more consistent, thus accelerating development timelines.
  • Time and resource management: The ÄKTA readyflux TFF system 500 features a single-use flow kit and easy-to-use UNICORN software, minimizing the need for specialized skills and reducing downtime.
  • Batch-to-batch consistency: Ensuring homogeneous mixing and batch-to-batch consistency is critical to maintaining product quality, maximizing yield, and enhancing process efficiency for low-volume applications. The ÄKTA readyflux TFF system 500 features active mixing via magnetic stirring, delivering controlled, reproducible mixing that ensures consistent performance across every batch.

Ludovic Brellier, President, Hardware Solutions, Cytiva, says, “Customers need robust solutions with industry leading technology, but also operational flexibility to manage lower volumes. The ÄKTA readyflux TFF system 500 is designed to provide these capabilities while maintaining the easy-to-use functions of the platform.” 

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Tags

AntibodiesAntibodies are used in techniques such as confocal and fluorescence microscopy, flow cytometry, ELISA, ELISPOT, immunohistochemistry, western blotting and immunopreciptation. Select specific antigen reactivity, high specific affinity, low non-specific binding, monoclonal or polyclonal, primary or secondary antibodies and associated conjugates such as an enzyme or dye for visualization.BiopharmaceuticalsBiopharmaceuticals are proteins and other compounds (such as nucleic acids) produced by living organisms that have uses as therapeutics or for in vivo diagnostics. The most well known example of a biopharmaceutical product, and the first to be approved for therapeutic use, was recombinant human insulin.Antibody Drug ConjugatesMonoclonal AntibodiesMonoclonal antibodies (mAbs) are lab-made molecules that can bind to specific antigens on cells, making them highly effective in treating cancers, autoimmune diseases, and infections. These targeted therapies are transforming the treatment landscape for many conditions. Browse our peer-reviewed product directory to find monoclonal antibodies for research and clinical applications; compare products, check reviews, and get pricing directly from manufacturers.